Abstract
Skeletal muscle abnormalities and loss are frequently present in patients with mild or moderate cardiac heart failure (CHF) and may contribute to fatigue and dyspnea. These muscle abnormalities may be associated with age related body composition changes, such as sarcopenia.
Muscle damage has also been observed in subjects with cardiac cahexia, a serious CHF complication, associated with poor prognosis independently of functional disease severity, age, and measures of exercise capacity and cardiac function. Loss of muscle mass is a feature of cachexia, whereas most sarcopenic subjects are not cachectic.
Individuals with no weight loss, no anorexia, and no measurable systemic inflammatory response may be sarcopenic.
Patients with severe CHF show multiple marked histological abnormalities of skeletal muscle, such as muscle fiber atrophy. These abnormalities are different in sarcopenia and cachexia. The majority of mechanisms involved in sarcopenia play a role even in the determination of cachexia and they are amplified in cachexia where they may induce both muscle damage as well as other abnormalities, such as fat and weight loss, through activation of lypolisis or anorexia.
To distinguish cachexia and sarcopenia in CHF patients, even if not easy, should be clinically relevant, because no specific treatment is available for cachectic patients whereas treatment options are possible for sarcopenia.
Keywords: Cachexia, heart failure, sarcopenia.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Sarcopenia, Cachexia and Congestive Heart Failure in the Elderly
Volume: 13 Issue: 1
Author(s): Mauro Zamboni, Andrea P. Rossi, Francesca Corzato, Clara Bambace, Gloria Mazzali and Francesco Fantin
Affiliation:
Keywords: Cachexia, heart failure, sarcopenia.
Abstract: Skeletal muscle abnormalities and loss are frequently present in patients with mild or moderate cardiac heart failure (CHF) and may contribute to fatigue and dyspnea. These muscle abnormalities may be associated with age related body composition changes, such as sarcopenia.
Muscle damage has also been observed in subjects with cardiac cahexia, a serious CHF complication, associated with poor prognosis independently of functional disease severity, age, and measures of exercise capacity and cardiac function. Loss of muscle mass is a feature of cachexia, whereas most sarcopenic subjects are not cachectic.
Individuals with no weight loss, no anorexia, and no measurable systemic inflammatory response may be sarcopenic.
Patients with severe CHF show multiple marked histological abnormalities of skeletal muscle, such as muscle fiber atrophy. These abnormalities are different in sarcopenia and cachexia. The majority of mechanisms involved in sarcopenia play a role even in the determination of cachexia and they are amplified in cachexia where they may induce both muscle damage as well as other abnormalities, such as fat and weight loss, through activation of lypolisis or anorexia.
To distinguish cachexia and sarcopenia in CHF patients, even if not easy, should be clinically relevant, because no specific treatment is available for cachectic patients whereas treatment options are possible for sarcopenia.
Export Options
About this article
Cite this article as:
Zamboni Mauro, Rossi P. Andrea, Corzato Francesca, Bambace Clara, Mazzali Gloria and Fantin Francesco, Sarcopenia, Cachexia and Congestive Heart Failure in the Elderly, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871530311313010008
DOI https://dx.doi.org/10.2174/1871530311313010008 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
Call for Papers in Thematic Issues
Advancing Therapies for Bone and Joint Diseases: Insights from Natural Products and Herbal Medicines
The aging global population is experiencing an increased risk of bone and joint health issues, notably osteoporosis and osteoarthritis, affecting over half of individuals over 60. Plant-based natural products and herbal medicines are gaining recognition as alternative therapies for these conditions, with secondary metabolites, including flavonoids, coumarins, and others, playing ...read more
Association between Diabetes Mellitus and natural product complementary applications: State of the arts
Diabetes Mellitus (DM) represents a significant global health challenge, characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The increasing prevalence of DM, alongside its associated complications, has prompted researchers and healthcare professionals to explore a variety of management strategies beyond conventional pharmacotherapy. Among these ...read more
Chronic inflammation and Disorders/Cancers
Chronic inflammation is fundamental cause of variety of disorders. Many lifestyle-related diseases including metabolic syndrome, obesity, impairment of immune responses, sepsis, mental illness, and other disorders are caused by chronic inflammation. Prevention of chronic inflammation is related to antiaging effects of our body. Proinflammatory cytokines such as TNF-α is associated ...read more
Immune defense of the blood-tissue barriers which are related to drugs, metabolic and hormones
We have already known that testis is an immune privilege area for the maintenance of spermatogenesis against to any pathogen from the interstitial area. With the BTB integrity there is a qualified selection for the mature sperm until the lumen migration which is sperm release progress. Spermiogenesis help for the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Indications for Infective Endocarditis Antibiotic Prophylaxis
Infectious Disorders - Drug Targets Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics Analysis
MicroRNA Host-Pathogen Interactions and the Pathological Consequences of Acute Systemic Candida albicans Infections in Mice
Current Drug Targets P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy
Current Drug Safety Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy
Current Topics in Medicinal Chemistry The Minority Aging Research Study: Ongoing Efforts to Obtain Brain Donation in African Americans without Dementia
Current Alzheimer Research Preface
Current Cardiology Reviews Anti-Inflammatory Treatments for Chronic Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews TGF-β: Its Role in Asthma and Therapeutic Potential
Current Drug Targets Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients
Current Drug Safety Screening for Silent Coronary Artery Disease in Diabetics- or Not?
Current Diabetes Reviews Oxidative Stress in Diabetic Nephropathy
Current Medicinal Chemistry Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Antisense Antibiotics: A Brief Review of Novel Target Discovery and Delivery
Current Drug Discovery Technologies Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Editorial [Hot Topic: Nitric Oxide and Hydrogen Sulfide - Contribution of Gaseous Messengers to the Cardiovascular Control (Guest Editor: Sona Cacanyiova)]
Current Pharmaceutical Biotechnology Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets Finerenone: A Novel Drug Discovery for the Treatment of Chronic Kidney Disease
Current Drug Discovery Technologies